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OBJECTIVES The purpose of this study was to examine the effect of intracoronary radiation therapy (IRT)
in diabetic patients with in-stent restenosis (ISR).
BACKGROUND Diabetic patients are at an increased risk for restenosis, repeat revascularization procedures
and late mortality after percutaneous coronary interventions and stenting. Intracoronary
radiation therapy, utilizing both gamma and beta-emitters, has been shown to reduce the rate
of ISR.
METHODS The study group consisted of 749 consecutive patients with ISR who were treated with either
IRT or placebo in randomized trials and registries at our center. Diabetic patients (252
radiation and 51 placebo) were compared with nondiabetic patients (371 radiation and 75
placebo).
RESULTS In-hospital outcomes were similar between diabetic and nondiabetic patients treated with and
without radiation. At six-month clinical and angiographic follow-up, there was a significant
reduction in the binary restenosis (63.8% vs. 15.7%, p  0.0001), target lesion revascular-
ization (66.7% vs. 17.6%, p  0.0001) and target vessel revascularization (TVR) (70.6% vs.
22.9%, p  0.0001) rates in diabetic patients treated with radiation compared to placebo.
Comparisons between the placebo arms detected a trend towards higher restenosis (63.8% vs.
48.4% p  0.13) and TVR (70.6% vs. 56.0%, p  0.14) in diabetic versus nondiabetic
patients. In contrast, diabetic and nondiabetic patients treated with IRT experienced similar
restenosis (15.6% vs. 10.7% p  0.33) and TVR (22.9% vs. 28.2% p  0.41) rates.
CONCLUSIONS In diabetic patients with ISR, intracoronary radiation significantly reduced the recurrence of
ISR compared to placebo. Additionally, similar rates of restenosis and revascularization
procedures were achieved in irradiated diabetic and nondiabetic patients. In view of these
results, IRT should be considered as a valuable therapeutic alternative in all diabetic patients
with ISR. (J Am Coll Cardiol 2002;39:1930–6) © 2002 by the American College of
Cardiology Foundation
Patients with diabetes mellitus (DM) referred for percuta-
neous coronary intervention (PCI) constitute one of the
greatest challenges for the interventional cardiologist. These
patients are usually older, female and sicker with more
frequent comorbid conditions, such as hypertension, hyper-
lipidemia and more advanced cardiovascular disease, as
manifested by multivessel coronary artery disease and con-
gestive heart failure (1). Restenosis continues to be the
major limitation of PCI, particularly in patients with DM.
Restenosis rates after balloon angioplasty in diabetic pa-
tients can be very high (up to 63%) (1–3), and although
stenting has been shown to decrease these rates, patients
with DM continue to have significantly higher restenosis
rates and clinical events following PCI (4–9).
Intracoronary radiation therapy (IRT), utilizing both
gamma- and beta-emitting sources, is a novel catheter-
based procedure that has demonstrated a reduction in
restenosis rates and the need for revascularization proce-
dures in a broad range of patients with ISR, as documented
in multiple, randomized, double-blind trials (10–12). The
objective of this report was to analyze the efficacy of IRT in
patients with DM and compare the outcomes of IRT and
placebo in diabetic versus nondiabetic patients.
METHODS
The Washington Radiation for In-Stent restenosis Trials
(WRIST) are a series of studies designed to assess the
benefit of IRT with either gamma- or beta-emitters in both
native coronary arteries and saphenous vein grafts for the
treatment of ISR. Details of these trials (SVG-WRIST,
WRIST, High dose and Long WRIST, Compassionate
USE, Plavix-WRIST and Beta WRIST) have been pub-
lished previously (10–13). All of these trials were sponsored
by an Investigational Device Exemption granted by the
Food and Drug Administration and approved by the Insti-
tutional Review Board and Radiation Safety Committee at
the Washington Hospital Center. These studies were mon-
itored by an external data and safety monitoring board, and
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clinical events were reviewed by an independent committee.
Informed consent was obtained from each patient before
enrollment into the study. All patients underwent coronary
intervention via the transfemoral approach with conven-
tional catheter-based systems according to current guide-
lines (14). Weight-adjusted heparin dosage was adminis-
tered during the procedure in order to maintain an activated
clotting time of 250 to 300 s and was routinely discontinued
at the end of the procedure. Patients received aspirin
325 mg at least 24 h before the procedure and continued
indefinitely afterwards. Patients were treated concomitantly
with either ticlopidine 250 mg twice daily or clopidogrel
75 mg a day for four weeks. Of this cohort, 120 patients
were treated with clopidogrel for six months. Glycoprotein
IIb/IIIa inhibitors were not used in these protocols. Patients
were followed clinically at 30 days and at 6 and 12 months.
Study population. Between February 1997 and February
2000, a total of 749 patients with ISR in their native
coronary artery or saphenous vein grafts were treated with
either IRT or placebo following conventional intervention.
Device selection, including atheroablative devices (rotation-
al and directional atherectomy or excimer laser angioplasty)
or additional stents, was left at the discretion of the
operator. In this cohort, 402 patients underwent random-
ization and 307 were treated in open registries, 303 patients
had DM, 252 were treated with IRT and 51 were random-
ized to the placebo arm. Of the 446 nondiabetic patients,
371 were treated with IRT and 75 were randomized to
placebo. Comparisons were made between the radiation and
placebo-treated groups in the diabetic and nondiabetic
population and between diabetic and nondiabetic patients.
Angiographic entry criteria included a diameter stenosis
50% within the stented area in vessels 2.5 to 5.0 mm in
diameter in patients who underwent successful angioplasty
(30% residual diameter stenosis in the absence of compli-
cations). Patients with a recent myocardial infarction (72 h),
left ventricular ejection fraction 20%, prior irradiation to
the chest, angiographic evidence of thrombus or multiple
lesions in the target vessel were excluded from the studies.
Diabetes mellitus: definitions. Patients were prospectively
classified as diabetic if they were treated with oral hypogly-
cemic drugs or insulin or if they had a previous history of
elevated fasting glucose (140 mg/dl) on at least two
separate occasions. According to the type of treatment,
patients were classified at the time of the initial procedure
into three categories: 1) diet only; 2) noninsulin-treated
diabetes mellitus (NITDM) (patients treated with oral
hypoglycemic drugs and diet, but without insulin); and 3)
insulin-treated diabetes mellitus (ITDM) (patients treated
with insulin, irrespective of other therapy).
Radiation delivery and dosimetry. For gamma radiation, a
192-Iridium source train was delivered into a noncentering
end-lumen catheter. The prescribed dose was either 14 or
15 Gy to a distance of 2.0 mm from the surface of the source
for vessels between 2.5 and 4.0 mm or 15 Gy to a distance
of 2.4 mm for vessels 4.0 mm in diameter. Maximal dose
to the near wall was55 Gy, whereas the minimum dose to
the far wall was7.3 Gy. For beta radiation, a 90-strontium
pure beta-emitter source was delivered into a centering
balloon end-lumen catheter. The prescribed dose was 20.6 Gy
to a distance 1.0 mm from the surface of the inflated balloon.
The dose rate varied from 16.0 to 5.6 Gy/min.
Quantitative coronary angiographic analysis. Quantitative
coronary angiographic analysis was performed by two inde-
pendent core laboratories blinded to the treatment proto-
cols, using the Cardiovascular Measurement System (ME-
DIS, Leiden, The Netherlands), as described previously
(10–13). Angiographic binary restenosis at follow-up was
defined as 50% diameter narrowing within the stent and
in the segment that included the stent plus its edges (5 mm
at each end). Total occlusion was considered to have a 100%
diameter stenosis.
Statistical analysis. The study population was analyzed in
three separate ways. First, patients were grouped by the
presence or absence of DM. Second, patients were grouped
based on whether they had received actual radiation treat-
ment or had been part of the placebo control group (n 
126). Third, the population of diabetic patients was sub-
grouped by the treatment modality into ITDM and
NITDM patients. Data are presented as mean  SD. For
continuous variables, comparisons between the two groups
were made with the Student t test and for categorical values
by the chi-square or Fisher exact test. Multivariate logistic
analysis with backward regression was used to model inde-
pendent predictors of restenosis and target vessel revascu-
larization (TVR). Variables included in the model were age,
gender, diabetes, hypertension, lesion length, postproce-
dural minimal lumen diameter and each one of the different
trials in order to assess the exact contribution of these
factors on restenosis rates. Statistical analysis was performed
with SAS software (SAS Institute, Cary, North Carolina).
A p value 0.05 was considered statistically significant.
RESULTS
The baseline clinical characteristics of the 749 patients
enrolled in the radiation trials for ISR are presented in
Table 1. Although there were no significant differences
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CI  confidence interval
DM  diabetes mellitus
ITDM  insulin-treated diabetes mellitus
IRT  intracoronary radiation therapy
ISR  in-stent restenosis
NITDM  noninsulin-treated diabetes mellitus
PCI  percutaneous coronary interventions
TLR  target lesion revascularization
TVR  target vessel revascularization
WRIST  Washington Radiation for In-Stent
restenosis Trial
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between patients assigned to IRT or placebo in either the
diabetic or the nondiabetic groups, diabetic patients had
more clinical characteristics that have been associated with a
worse outcome, including a significantly higher percentage
of women, hypertension and lower left ventricular ejection
fraction than patients without DM. Angiographic and
procedural characteristics are shown in Table 2. Diabetic
patients had a trend towards more long, diffuse ISR,
although of borderline statistical significance (p  0.09),
whereas nondiabetic patients in the placebo arm had a lower
percentage of vein graft lesions and total occlusions (TIMI
flow 0 to 1) (p  0.08) and a higher percentage of ostial
lesions compared to nondiabetic patients treated with radi-
ation or to diabetic patients (p  0.002) (15).
The results of quantitative coronary angiography analysis
are summarized in Table 3. Baseline and postprocedural
vessel lumen dimensions were smaller in diabetic patients
than in nondiabetics. In-hospital outcomes were similar
between the groups, with 100% procedural success in all
groups and similar death, myocardial infarction and repeat
angiography rates. The contribution of each one of the
different trials to the pooled results and the TVR rates for
each trial are shown in Table 4. On multivariate analysis,
only lesion length was an independent predictor of TVR
(OR  1.02; 95% confidence interval [CI]  1.01 to 1.04,
p  0.01) and target lesion revascularization (TLR) (OR 
1.03; 95% CI  1.01 to 1.05, p  0.01).
Diabetes group: radiation versus placebo. Clinical events
at six-month follow-up are depicted in Table 5 and Figures
1 to 3. Restenosis rates were reduced by 76% in diabetic
patients treated with radiation, compared to those patients
in the placebo arm of the study (p  0.0001) (Fig. 1). Rates
of TLR and TVR were also significantly reduced in com-
parison to the placebo arm (Figs. 2 and 3). Higher revas-
cularization rates, especially TVR, than restenosis rates can
be attributed to edge effect, operators biased to treat
borderline lesions (50% stenosis) and progression of
disease in these patients. Non-TVR rates were similar in the
radiation and the placebo arms (11.8% vs. 7.8%, p  0.62).
Mortality rates were similar between the two groups, as
were the rates of late total occlusion. There was a higher rate
of myocardial infarction in IRT-treated patients, which
could be attributed to a surprisingly low rate of non–Q-wave
myocardial infarction in the placebo group. Major adverse
cardiac events (death, myocardial infarction and repeat
revascularization) were significantly lower in patients treated
with intracoronary radiation, 25.3% versus 70.6%, p 
0.0001, compared to placebo.
Table 1. Clinical Characteristics
Diabetics (n  303) Nondiabetics (n  446)
Radiation
(n  252)
Placebo
(n  51)
Radiation
(n  371)
Placebo
(n  75)
Age (yrs) 62.1  10.4 63.2  9.04 61.6  11.6 60.1  10.6
Male gender (%) 59.5* 52.9 71.4 77.3
Unstable angina (%) 84.5 82.4 78.7 78.6
Diabetes controlled by
Diet alone (%) 9.9 11.8 NA NA
Oral drugs (%) 44.8 47.1 NA NA
Insulin (%) 45.2 41.2 NA NA
Hypertension (%) 82.1† 78.4 66.0 58.7
Hyperlipidemia (%) 89.5 88.2 83.5 86.7
Prior smoker (%) 52.8 60.8 53.1 44.0
Prior MI (%) 55.2 47.1 50.9 53.3
Prior CABG (%) 58.0 45.1 51.9 44.6
Ejection fraction (%) 46  12‡ 50  11 49  12 50  13
pNS for comparison between radiation vs. placebo in diabetic and nondiabetic patients. *p 0.003 for diabetic vs. nondiabetic
patients treated with intracoronary radiation. †p  0.0001 for diabetic vs. nondiabetic patients treated with intracoronary
radiation. ‡p  0.002 for diabetic vs. nondiabetic patients treated with intracoronary radiation.
CABG  coronary artery bypass graft surgery; MI  myocardial infarction.
Table 2. Angiographic Characteristics
Diabetics
(n  303)
Nondiabetics
(n  446)
Radiation
(n  252)
Placebo
(n  51)
Radiation
(n  371)
Placebo
(n  75)
Target site
Left main (%) 5.6 3.9 3.0 4.0
LAD (%) 20.5 23.5 23.5 25.3
LCx (%) 28.6* 25.5 20.4 28.0
RCA (%) 24.8* 29.4 36.6 34.7
SVG (%) 20.5 17.6 16.5 8.0
Ostial lesion (%) 8.8 9.8 8.9 16.0*
Lesion length (mm) 24.2 24.3 24.7 24.9
Pre-TIMI flow 0–1 (%) 9.8 6.3 10.2 17.1
Focal lesion (%) 10.4 18.4 15.3 12.7
Diffuse lesion (%) 75.9 67.5 65.3 72.7
Device used
Balloon only (%) 12.3 7.8 14.6 9.3
Rotational atherectomy (%) 44.8 58.8 48.2 56.0
Excimer laser (%) 27.8 25.5 27.5 26.7
Additional stent (%) 46.4 43.1 42.0 45.3
p  NS for radiation vs. placebo in diabetic and nondiabetic patients. *p  0.002 for
diabetic vs. nondiabetic patients treated with intracoronary radiation.
LAD  left anterior descending artery; LCx  left circumflex artery; RCA 
right coronary artery; SVG  saphenous vein graft; TIMI  Thrombolysis In
Myocardial Infarction.
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Irradiated arm diabetic versus nondiabetic patients. As
shown in Table 5 and Figures 1 to 3, event-free survival
(freedom from death, myocardial infarction and repeat
revascularization) was 74.7% in the diabetic group com-
pared to 70.7% in the nondiabetic group (p  0.20).
Mortality rates were low and similar between diabetic and
nondiabetic patients, 3.7% versus 2.4% (p  0.38), respec-
tively. Rates of TLR by either balloon angioplasty or coronary
artery bypass graft surgery (CABG) were also similar between
the two groups, although there was a trend towards a higher
rate of TVR by CABG in nondiabetic patients treated with
radiation, 9.8% versus 5.7% in diabetics treated with radiation
(p 0.09). Late total occlusion rates were also similar between
the two groups, 5.3% versus 6.2% (p  0.62), respectively. At
the six-month angiographic follow-up, late lumen loss was
0.51  0.75 mm for diabetic patients compared with 0.48 
0.75 for nondiabetic patients (p 0.81) treated with radiation
and the late loss index was 0.68  0.75 compared to 0.52 
1.17 (p  0.33), respectively.
Placebo arm: diabetic versus nondiabetic patients. During
the performance of these trials, 126 patients underwent
randomization to the placebo arm (no radiation); 38% (n 
51) of them had DM. Nondiabetic patients in the placebo
arm had smaller vessel lumen diameters at the lesion site
before the procedure than did nondiabetic patients treated
with radiation (Table 3). This was corrected with the
intervention and resulted in a significantly greater acute gain
in this group of patients (1.02  0.49 versus 1.22  0.57,
p  0.01), respectively. At six-month angiographic follow-
up, diabetic patients treated with placebo had a trend
toward higher restenosis rates (63.8% vs. 48.4%, p  0.13),
TLR rates (66.7% vs. 54.7%, p  0.20) and TVR rates
(70.6% vs. 56.0%, p  0.14) compared to nondiabetic
patients, respectively. Late total occlusion rates were similar
between the two groups.
ITDM versus NITDM. Analysis of the data based on the
type of diabetes revealed similar event-free survival, 74.1%
in the ITDM versus 76.7% in NITDM patients treated
with IRT (p  0.64), and similar restenosis rates at
six-month angiographic follow-up, 14.1% and 17.1%, re-
spectively (p  0.62). Both groups had comparable rates of
TLR, 19.6% versus 17.1%, respectively (p 0.46), although
more ITDM patients underwent TLR by coronary artery
bypass graft surgery (8.0%) compared with NITDM pa-
tients (2.3%) (p  0.04). Late total occlusion rates were
higher in ITDM patients (8.0% vs. 3.0%, p  0.08).
Table 4. Target Vessel Revascularization Rates in the Different Trials
Diabetics Nondiabetics
TotalRadiation Placebo Radiation Placebo
SVG-WRIST 2/17 (12%) 4/9 (44%) 8/26 (31%) 4/6 (67%) 58
WRIST 7/46 (17%) 16/20 (80%) 19/62 (31%) 19/30 (63%) 158
High dose and Long WRIST 17/69 (25%) 16/22 (73%) 23/96 (24%) 19/39 (49%) 226
Compassionate WRIST 14/56 (25%) 24/74 (32%) 130
Plavix-WRIST 12/49 (25%) 19/76 (25%) 125
Beta WRIST 6/15 (40%) 12/37 (32%) 52
Total 52/52 (21%) 36/51 (71%) 104/371 (28%) 42/75 (56%) 749
SVG  saphenous vein graft; WRIST  Washington Radiation for In-Stent restenosis Trial.
Table 3. Quantitative Angiographic Analysis
Diabetics (n  303) Nondiabetics (n  446)
Radiation
(n  252)
Placebo
(n  51) p Value
Radiation
(n  371)
Placebo
(n  75) p Value
Baseline
RVD (mm) 2.56  0.58 2.67  0.58 0.58 2.70  0.54 2.64  0.52 0.48
DS (%) 69  16 69  14 0.92 64  14 73  16 0.0001
MLD (mm) 0.82  0.42* 0.82  0.40 0.96 0.96  0.43 0.71  0.44 0.0002
Postprocedure
DS (%) 31  12 31  11 0.69 28  12 29  13 0.46
MLD (mm) 1.83  0.40* 1.87  0.37 0.54 1.98  0.46 1.94  0.46 0.53
Acute gain (mm) 1.01  0.51 1.06  0.53 0.65 1.02  0.49 1.22  0.57 0.01
At six-month follow-up
RVD (mm) 2.69  0.44 2.74  0.60 0.63 2.78  0.51 2.76  0.52 0.80
DS (%) 50  28 66  21 0.0003 47  25 58  20 0.0006
MLD (mm) 1.40  0.78 0.96  0.74 0.004 1.54  0.78 1.17  0.62 0.0004
Late loss (mm) 0.51  0.75 0.91  0.68 0.004 0.48  0.75 0.78  0.58 0.003
LTO (%) 5.3 2.0 0.47 6.2 1.3 0.1
*p  0.01 for diabetic vs. nondiabetic patients treated with intracoronary radiation.
DS  diameter stenosis; LTO  late total occlusion; MLD  minimal lumen diameter; RVD  reference vessel diameter.
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DISCUSSION
This study used pooled data to compare the in-hospital and
six-month clinical and angiographic outcomes of diabetic
and nondiabetic patients who underwent IRT for the
prevention of recurrence of ISR in the WRIST studies.
Diabetic patients randomized to the placebo arm had a
trend towards higher event rates, including restenosis, TLR
and TVR, compared with nondiabetic patients also ran-
domized to the placebo arm, as shown in previous studies,
although statistical significance was not reached for any
parameter. In this cohort, diabetic patients had smaller
vessel dimensions at baseline and at the end of the proce-
dure and a trend towards more diffuse type of ISR. Despite
this, there were no differences in the TLR and TVR rates or
the restenosis rates at six-month angiographic follow-up in
the radiation group when compared with the nondiabetic
group. Comparison by treatment modality (radiation vs.
placebo) detected a 76% reduction in the restenosis rates in
diabetic patients treated with radiation, a 74% reduction in
TLR rates and a 68% reduction in TVR rates, which was
slightly higher (not significantly) than the reduction
achieved in nondiabetic patients and in previous radiation
trials (11,12).
These results warrant several comments. First, the per-
cutaneous treatment of ISR with conventional methods is
associated with high failure rates in both diabetic and
nondiabetic patients. Second, IRT for the prevention of
recurrence of ISR significantly reduced restenosis and re-
vascularization procedures in diabetic patients. The pro-
nounced reduction in event rates in the diabetic patients is
underscored by the increased recurrence of adverse events
seen in the placebo group. Third, diabetic patients respond
to intracoronary radiation in a similar fashion as nondiabetic
patients treated with intracoronary radiation, which equal-
izes the outcome of nondiabetic and diabetic patients.
Finally, when diabetic patients were compared according to
therapeutic regimen, patients with ITDM and NITDM
had similar event-free survival, mortality, revascularization
procedures and restenosis rates, although there was a higher
incidence of TLR by bypass surgery in the ITDM group of
patients compared with NITDM patients. Previous studies
have shown that patients with ITDM have a higher inci-
Figure 1. Binary restenosis rates at six-month angiographic follow-up between patients treated with intracoronary radiation versus patients randomized to
the placebo arm. White bars placebo; black bars radiation.
Table 5. Clinical and Angiographic Six-Month Follow-Up
Diabetes (n  303) Nondiabetic (n  446)
Radiation
(n  252)
Placebo
(n  51) p Value
Radiation
(n  371)
Placebo
(n  75) p Value
Death (%) 3.7 5.9 0.44 2.4 4.0 0.44
MI (%) 19.6 5.9 0.04 15.2 17.3 0.48
Q-wave (%) 1.2 0 NS 0.8 0 NS
Non–Q-wave (%) 18.4 5.9 0.04 14.4 17.3 0.48
TLR (%) 17.6 66.7 0.0001 19.2 54.7 0.0001
By PTCA (%) 13.5 60.8 0.0001 13.6 53.3 0.0001
By CABG (%) 4.9 7.8 0.49 7.3 5.3 0.80
TVR (%) 22.9 70.6 0.0001 28.2 56.0 0.0001
By PTCA (%) 18.4 64.7 0.0001 20.9 53.3 0.0001
By CABG (%) 5.7 7.8 0.53 9.8 6.7 0.51
MACE free (%) 74.7 29.4 0.0001 70.7 42.7 0.0001
Restenosis (%) 15.6 63.8 0.0001 10.7 48.4 0.0001
p  NS for diabetic vs. nondiabetic patients treated with intracoronary radiation.
CABG  coronary artery bypass graft surgery; MACE  major adverse cardiac events (death, myocardial infarction and
target vessel revascularization); MI  myocardial infarction; PTCA  percutaneous transluminal coronary angioplasty; TLR 
target lesion revascularization; TVR  target vessel revascularization.
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dence of in-hospital mortality, higher TLR rates and
significantly lower event-free survival when compared with
patients with NITDM (5,16,17). Late total occlusion due to
late thrombotic events (30 days after the index procedure),
one of the main complications of intracoronary radiation
(18,19), was not encountered more frequently in diabetic
patients compared with nondiabetic patients, despite previ-
ous reports that have shown a trend toward higher rates of
subacute stent thrombosis in diabetic patients who undergo
stenting (5–16). The trend toward a higher incidence of late
total occlusion in ITDM patients suggests that diabetic
status may play an important role in terms of progression of
the disease, which may lead to a higher incidence of late
total occlusion in this subset of patients. Given the very
small number of patients, this sort of analysis is clearly
hypothesis-generating.
Stent-based delivery of sirolimus has recently been shown
to be feasible and effective in reducing in-stent neointimal
hyperplasia by inhibiting cellular proliferation (20). Although
the use of drug-eluting stents in the diabetic population may
decrease the proportion of diabetic patients with ISR and alter
the management of coronary revascularization, the perfor-
mance of this stent in diabetic patients is not yet known.
Study limitations. The present study was a retrospective
analysis of pooled data obtained from a heterogeneous
group of patients who were enrolled in registries and
randomized clinical studies. Therefore, the results and
conclusions are subject to the limitations inherent in all such
reports. The current analysis is limited to patients under-
going intervention for ISR, and the results cannot be
generalized to the entire diabetic population that undergo
PCI. Comparing results among the randomized and non-
randomized trials, taking into account different types of
lesions, different types of patients and different types of
radiation into a pooled analysis, may be somewhat impre-
cise. Finally, the relatively small number of patients in the
placebo arm, especially during the analysis by treatment
regimen, is clearly hypothesis-generating and may lead us to
incur a type II statistical error.
Clinical implications. Patients with DM referred for PCI
constitute one of the greatest challenges faced by the
interventional cardiologist in the present era. In view of the
results obtained in this study, IRT should be considered as
a valuable therapeutic alternative in all diabetic patients with
ISR, and needs confirmation in a randomized, controlled
setting.
Figure 2. Target lesion revascularization rates at six-month follow-up in patients treated with intracoronary radiation and patients randomized to the
placebo arm. White bars placebo; black bars radiation.
Figure 3. Target vessel revascularization rates at six-month follow-up in patients treated with intracoronary radiation and patients randomized to the
placebo arm. White bars placebo; black bars radiation.
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